Tokyo - Delayed Quote JPY

Immuno-Biological Laboratories Co., Ltd. (4570.T)

450.00
-2.00
(-0.44%)
At close: 3:30:00 PM GMT+9
Loading Chart for 4570.T
  • Previous Close 452.00
  • Open 457.00
  • Bid 450.00 x --
  • Ask 453.00 x --
  • Day's Range 450.00 - 457.00
  • 52 Week Range 356.00 - 603.00
  • Volume 16,300
  • Avg. Volume 108,830
  • Market Cap (intraday) 4.191B
  • Beta (5Y Monthly) 0.05
  • PE Ratio (TTM) 18.10
  • EPS (TTM) 24.86
  • Earnings Date May 14, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Mar 27, 2013
  • 1y Target Est --

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.

www.ibl-japan.co.jp

57

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 4570.T

View More

Performance Overview: 4570.T

Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4570.T
2.39%
Nikkei 225 (^N225)
12.60%

1-Year Return

4570.T
2.39%
Nikkei 225 (^N225)
7.15%

3-Year Return

4570.T
41.51%
Nikkei 225 (^N225)
28.64%

5-Year Return

4570.T
21.05%
Nikkei 225 (^N225)
79.46%

Compare To: 4570.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4570.T

View More

Valuation Measures

Annual
As of 4/22/2025
  • Market Cap

    4.21B

  • Enterprise Value

    3.68B

  • Trailing P/E

    18.19

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.70

  • Price/Book (mrq)

    3.15

  • Enterprise Value/Revenue

    4.11

  • Enterprise Value/EBITDA

    21.80

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    31.54%

  • Return on Assets (ttm)

    8.71%

  • Return on Equity (ttm)

    23.95%

  • Revenue (ttm)

    948M

  • Net Income Avi to Common (ttm)

    299M

  • Diluted EPS (ttm)

    24.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    753M

  • Total Debt/Equity (mrq)

    13.59%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 4570.T

View More

Company Insights: 4570.T

Research Reports: 4570.T

View More

People Also Watch